Alumina Matrix Composite Ceramic Bearing Total Hip Arthroplasty in Patients Younger Than 30 Years

Seoul National University Bundang Hospital92 enrolled

Overview

This study will evaluate clinical outcome on patients who undergo cementless 4th generation ceramic (BIOLOX®delta, CeramTec GmbH, Plochingen, Germany) on ceramic (CoC) bearing total hip aArthroplasty ("THA") in patients younger than 30 years.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Hip Disease

Interventions

THA using 4th generation CoCDEVICE

Eligibility

Sex: ALLMin age: 15 YearsMax age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * younger than 30 years * advanced hip disease Exclusion Criteria: * older than 30 years

Outcomes

Primary Outcomes

survival rate of 4th generation ceramic-on-ceramic THA

survival rate of 4th generation ceramic-on-ceramic THA end point for best senario ; any reoperation end point for moderate senario ; loosening end point for worst senario ; osteolysis

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.